2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 882

A Signature of microRNAs Overexpressed in Inflamed Temporal Arteries of Patients with Giant Cell Arteritis
Abstract Number: 1107

A Strong Association Between Memory Loss and Word Finding Difficulties in Fibromyalgia
Abstract Number: 505

A Structured Approach for Comparative Benefit-Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis
Abstract Number: 577

A Substantial Decrease in Work Productivity and Physical Health-Related Quality of Life in Chronic Back Pain of Recent Onset: Data from the SPACE-Cohort
Abstract Number: 1358

A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women
Abstract Number: 1660

A Systematic Review and Network Meta-Analysis of Cyclophosphamide and Mycophenolate Mofetil in Lupus Nephritis
Abstract Number: 962

A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis
Abstract Number: 2325

A Systematic Review of the Educational Approach of Occupational Therapy for Rheumatoid Arthritis
Abstract Number: 851

A Tailored Approach to Reduce Dose of Anti-TNF Drugs Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Propensity Score-Matched Cohort Study
Abstract Number: 2422

A Tailored Approach to Reduce Dose of TNF Inhibitors Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Rheumatoid Arthritis over One and Two Years: A Prospective Cohort Study
Abstract Number: 2102

A Tissue-Specific Lincrna in the TRAF1-C5 Risk Locus As a Putative Cis-Regulator, Bridging Genetics and Disease
Abstract Number: 2034

A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA)
Abstract Number: 937

A Unique Role for IL-18 Receptor-α in Monocyte Migration in RA and K/BxN Serum Transfer Arthritis
Abstract Number: 456

AAA-Atpase p97 Regulates Autophagy-Associated Cell Death in Arthritis
Abstract Number: 504

Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries

« Previous Page
1
…
6
7
8
9
10
…
202
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].